LONDON, England, May 19 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma

* Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7

* Blenrep combinations could redefine treatment as early as first . . .

Click here for more information about our products